

12 Aug 2024 | News

## **Quick Listen: Scrip's Five Must-Know Things**

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer's crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 August 2024, including: <u>Amgen, Inc.</u> positions for obesity and diabetes; <u>Bristol Myers Squibb Company</u> returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in <u>Bayer AG</u>'s crown?; Japan pharma firms cut jobs; and <u>Sun Pharmaceutical Industries Ltd.</u> seeks GLP-1 partner.

This and all our other podcasts are available on the *Citeline* channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Amgen Gets Into Position For MariTide Development" - Scrip, 6 Aug, 2024.)

(Also see "BMS Returns TIGIT Bispecific To Agenus Amid Pipeline Reshuffle" - Scrip, 5 Aug, 2024.)

(Also see "Kerendia Could Be Next Jewel In Bayer's Pharma Crown" - Scrip, 6 Aug, 2024.)

(Also see "*Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts*" - Scrip, 7 Aug, 2024.)



(Also see "*Sun Seeks Partner For GLP-I Asset, Legal Challenge Clouds Alopecia Drug Launch*" - Scrip, 5 Aug, 2024.)

Click here to explore this interactive content online  $^{2}$